1. Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients.
- Author
-
Droc G, Istrate M, Mercan-Stanciu A, Dodot M, Isac T, Toma L, Zgura A, Trifan A, Serbanica AN, Iliescu L, and Micu L
- Subjects
- Humans, Antiviral Agents adverse effects, Ritonavir adverse effects, Hepacivirus genetics, Drug Therapy, Combination, Valine therapeutic use, Genotype, Carbamates adverse effects, Anilides adverse effects, Renal Dialysis adverse effects, Bilirubin therapeutic use, Transaminases therapeutic use, Fatigue, Headache chemically induced, Headache drug therapy, Nausea chemically induced, Proline therapeutic use, Treatment Outcome, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Macrocyclic Compounds adverse effects, Hepatitis C
- Abstract
Background/aim: The aim of this study was to determine the safety and efficacy of a direct-acting antiviral treatment, ombitasvir/paritaprevir/ritonavir and dasabuvir, without ribavirin, in a real-life setting., Patients and Methods: We performed a prospective observational study including 108 patients undergoing hemodialysis for end-stage kidney disease, referred to our clinic for antiviral therapy for chronic hepatitis C virus infection. Patients received treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, for 12 weeks. Sustained virologic response (SVR) was defined as undetectable viremia at 12 weeks after the end of therapy. For safety analysis, we monitored serum levels of hemoglobin, albumin, total bilirubin, alanine-aminotransferase and aspartate- aminotransferase at the beginning and end of therapy, as well as at SVR. Verbal Numeric Rating Scale was used to assess the presence of nausea, headaches and fatigue., Results: We noted a high prevalence of diabetic and hypertensive nephropathy as the underlying cause of chronic kidney disease. Most of the patients had F2 and F3 liver fibrosis (32.40% and 34.25%, respectively). The SVR rate was 96.2% (103/107 patients). We recorded an unrelated death after the completion of antiviral therapy. We found increased levels of nausea, headaches and fatigue at the end of therapy compared to at initiation, The presence and degree of symptoms did not correlate with the underlying cause of renal disease (p=0.72) nor with the degree of fibrosis (p=0.08). Minimal increases in transaminases and bilirubin were recorded at the end of treatment, with no statistical significance., Conclusion: Oral antiviral therapy with ombitasvir/paritaprevir/ritonavir and dasabuvir can be safely used in hemodialysis patients, with similar response rates compared to the general population., (Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF